Cat. #140061
GCGR E20 Cell line
Cat. #: 140061
Organism: Human
Tissue: Grade IV Glioblastoma
Model: Primary cell line
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Gillian Morrison, Steven Pollard
Institute: University of Edinburgh
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: GCGR E20 Cell line
- Cancer type: Brain cancer
- Cancers detailed: Glioblastoma
- Organism: Human
- Tissue: Grade IV Glioblastoma
- Morphology: Adherent monolayer with stem-like features (SOX2, NESTIN).
- Growth properties: Adherent
- Model: Primary cell line
- Description: GCGR E20 is a primary, patient-derived, IDH-wildtype glioblastoma stem-like cell line generated to provide a physiologically relevant model of primary GBM. It exhibits a proneural transcriptional profile, a GBM_RTK_I methylation subclass, and grows as an adherent, laminin-dependent monolayer with a doubling time of ~159 hours. GCGR E20 is tumourigenic in vivo, forming tumours after around four months, and is supported by extensive molecular profiling including RNAseq, WGS, and EPIC methylation arrays. GCGR E20 is widely used for studying glioblastoma stem-like cell behaviour and treatment response, with applications in 2D viability assay. It has also been used in drug-combination studies, including MEK/FAK inhibitor synergy screens across diverse GSC panels. Additionally, GCGR E20 exhibits undetectable BTK protein, distinguishing it from BTK active GBM tissues
- Application: Used to study proneural GBM, and drug response.
- Production details: Derived from surgically resected primary glioblastoma tissue and expanded as an adherent monolayer under laminin supported condition
- Biosafety level: 2
- Recommended controls: GCGR human neural stem cell lines
Applications
- Application: Used to study proneural GBM, and drug response.
Handling
- Format: Frozen
- Growth medium: Serum‑free DMEM/HAMS‑F12 (“Complete + EFL”) supplemented with glucose, NEAA, B27, N2, BSA, beta‑mercaptoethanol, Pen/Strep, and recombinant EGF (10 ng/mL), FGF‑2 (10 ng/mL), plus laminin‑1 (2 ug/mL). Laminin is required for adherent growth.
- Subculture routine: Passage at 80–90% confluence; split 1:4–1:6; detach using Accutase; avoid over‑dilution; replace medium weekly
- Cultured in antibiotics: Pen/Strep
- Characterisation tests: RNA‑seq, methylation array, WGS, copy‑number profiling; STR profile available
